Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Holdings Increased by Cerity Partners LLC

Cerity Partners LLC boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 6.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 42,951 shares of the medical equipment provider's stock after acquiring an additional 2,644 shares during the period. Cerity Partners LLC's holdings in Zimmer Biomet were worth $4,587,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ZBH. FMR LLC grew its holdings in Zimmer Biomet by 91.6% in the 4th quarter. FMR LLC now owns 1,438,011 shares of the medical equipment provider's stock valued at $151,897,000 after buying an additional 687,675 shares during the period. Aster Capital Management DIFC Ltd raised its stake in Zimmer Biomet by 5,482.4% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 4,745 shares of the medical equipment provider's stock worth $501,000 after purchasing an additional 4,660 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of Zimmer Biomet by 24.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 250,194 shares of the medical equipment provider's stock valued at $26,428,000 after buying an additional 49,821 shares during the period. Aviva PLC raised its position in shares of Zimmer Biomet by 103.7% in the 4th quarter. Aviva PLC now owns 122,774 shares of the medical equipment provider's stock worth $12,969,000 after buying an additional 62,507 shares during the period. Finally, Rhenman & Partners Asset Management AB purchased a new stake in Zimmer Biomet during the fourth quarter valued at about $13,098,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.95% of the company's stock.

Zimmer Biomet Stock Up 1.0 %

Shares of ZBH stock traded up $0.96 during trading hours on Friday, hitting $97.90. 4,367,870 shares of the company were exchanged, compared to its average volume of 1,650,696. The business's 50-day simple moving average is $105.95 and its two-hundred day simple moving average is $106.78. Zimmer Biomet Holdings, Inc. has a one year low of $96.58 and a one year high of $123.96. The stock has a market capitalization of $19.37 billion, a price-to-earnings ratio of 22.00, a P/E/G ratio of 1.95 and a beta of 0.84. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm earned $2.20 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.98%. Zimmer Biomet's payout ratio is currently 21.57%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research reports. Stifel Nicolaus boosted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Royal Bank of Canada cut their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a research report on Monday. Truist Financial reissued a "hold" rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Finally, Barclays lowered their target price on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, Zimmer Biomet has an average rating of "Hold" and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.